Human T-cell lymphotropic virus type-1 (HTLV-1)-associated bronchioloalveolar disorders (HABAs) are pulmonary disorders with various interstitial lung disease patterns that often occur in HTLV-1 carriers. Among HABAs, organizing pneumonia (OP) is extremely rare. We present a case of an 82-year-old woman with OP as a HABA. This patient responded to corticosteroid therapy; however, the patient required the continuation of oral corticosteroid therapy to avoid OP relapse. In cases of OP as a HABA that are not stabilized by treatment with corticosteroids, continuation of oral corticosteroid therapy might be considered.
H uman T-cell lymphotropic virus type-1 (HTLV-1) is a retrovirus that causes adult T-cell leukemia/ lymphoma (ATL). In HTLV-1 carriers, pulmonary disorders with various interstitial lung disease patterns often occur [1] and are known as HTLV-1-associated bronchioloalveolar disorders (HABAs). [2] Among HABAs, organizing pneumonia (OP) is extremely rare. [3] Therefore, the efficacy of corticosteroid therapy for OP as a HABA has not been established. Herein, we present a case of OP that was relatively refractory to corticosteroid therapy.
Case Report
An 82-year-old woman, who was a nonsmoker and had no remarkable personal or family medical history, presented with exertional breathlessness. She had no fever or sore throat. A physical examination revealed no remarkable abnormalities; breath sounds and skin appearance were normal. However, chest radiography showed airspace consolidations in the bilateral lung fields [ Figure 1a ], and chest computed tomography showed airspace consolidations along the bronchovascular bundles and bronchiectasis [ Figure 1b ]. Serum levels of Chlamydophila pneumoniae a n d M y c o p l a s m a p n e u m o n i a e I g M antibodies were not increased. Antibiotic administration did not improve the chest radiography findings. The patient tested positive for serum anti-HTLV-1 antibodies and was therefore diagnosed with HTLV-1 carrier. The levels of other viral serum IgM antibodies, such as cytomegalovirus, herpes simplex virus, herpes zoster virus, and Epstein-Barr virus VCA-IgM, were not increased. Pulmonary function tests were performed; vital capacity (VC) was 1.71 L (81.4%); forced expiratory volume in 1 s (FEV1) was 1.30 L; FEV1/forced vital capacity (FVC) was 72.63%; and carbon monoxide diffusing capacity (DLCO) was 5. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com pulmonary lesion, the patient was diagnosed with OP [ Figure 2 ]. The bronchoalveolar lavage fluid (BALF) showed a slightly elevated cell concentration (484 cells/ μL), and 50% of these cells were lymphocytes. The lymphocyte subsets of BALF were as follows: CD3 (87.4%), CD4 (54.0%), CD8 (37.5%), and the CD4/CD8 ratio was 1.44. A culture of the BALF detected no pathogenic microorganisms. She had no prior use of medical drugs. In addition, we detected no autoantibodies or malignancies. Hence, the final diagnosis was OP as a HABA.
She was administered a 30-mg dose of oral prednisolone daily. Even after 10 days of treatment, chest radiography findings and breathlessness did not improve significantly. Therefore, she was administered 250 mg/day of intravenous methylprednisolone for 3 days followed by 20 mg/day of oral prednisolone. An improvement was observed in chest radiography findings [ Figure 3 ] and breathlessness. Pulmonary function improved as follows: VC was 2.03 L (96.7%), FEV1 was 1.49 L, FEV1/FVC was 77.60%, and DLCO was 6.41 mL/min/mmHg (33.7%). Therefore, the prednisolone dose was tapered to 2 mg/day. This dose was maintained to avoid the possibility of an OP relapse. The OP has been stable for 17 months, with no ATL cells detected in the peripheral blood.
Discussion
In this case report, we have presented two important clinical observations. First, OP can occur in an HTLV-1 carrier. To the best of our knowledge, only two cases of OP in HTLV-1 carriers have been reported previously. [4, 5] Known causes and associations of secondary OP include medical-related drugs, infections, inflammation, malignancy, transplantation, interstitial lung disease, and miscellaneous lung injury. [6] In the present case, none of the known causes or associations of OP were found. However, as the patient was an HTLV-1 carrier, diagnosing the OP as a HABA in the present case is justified.
Second, OP as a HABA may be effectively treated with corticosteroids as previously reported. [4, 5] In general, OP responds rapidly to oral corticosteroid therapy. The present case also showed the efficacy of corticosteroid therapy. However, the present case required continuation of oral corticosteroid therapy to avoid OP relapse. In cases of OP as a HABA that are not stabilized by treatment with corticosteroids, continuation of oral corticosteroid therapy might be considered.
The increment of CD4/CD8 ratio in BALF might be a feature of OP as a HABA. Considering cryptogenic OP, it has been reported that the CD4/CD8 ratio decreases. [7] Moreover, it has been reported that CD4+ and CD25+ lymphocytes increase in the BALF of HABA. [1] To evaluate the usefulness of the examination of CD4/CD8 ratio in BALF for the diagnosis of OP as a HABA, accumulation of BALF data of OP as a HABA is required.
HTLV-1 infection is endemic in Japan, Africa, the Caribbean islands, and Central and South America. [8] However, because of immigration, HTLV-1 carriers can be found in many other regions of the world. Based on the findings of this report, if a patient presents with OP 
Conclusion
We report a rare case of OP as a HABA. OP as a HABA may be effectively managed with acute corticosteroid therapy; however, if stabilization of the patient's condition is not achieved, continuation of oral corticosteroid therapy might be considered.
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